At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Lanreotide (Autogel formulation) and Temozolomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Lanreotide ATG 120 mg in Combination With Temozolomide in Subjects With Progressive Well Differentiated Thoracic Neuroendocrine Tumors. A Phase II, Multicentre, Single Arm, Open-label Trial.
In Brief
A Phase 2 clinical trial evaluating Lanreotide (Autogel formulation) and Temozolomide for Neuroendocrine Tumours. Completed, enrolled 40 participants across 10 sites.
Detailed Summary
The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg in combination with Temozolomide in subjects with unresectable advanced neuroendocrine tumours of the lung or thymus as Disease Control Rate at 9 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumours
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartJul 2016
Primary CompletionFeb 2019
Study CompletionJun 2019
TodayJul 2026
First PostedMar 3, 2016
Enrollment StartJul 1, 2016
Primary CompletionFeb 8, 2019
Study CompletionJun 18, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.3 years ago
Interventions
Lanreotide (Autogel formulation) and Temozolomidedrug